A biotechnology and pharmaceutical giant wanted to create a campaign measuring the ability of governments' biopharma strategies to withstand economic and pandemic shocks
Objective
A survey of top biopharma executives in Europe indicates how increased government participation in the business during Covid-19 has impacted areas including drug approval speed, supply chain resilience, and medication affordability
Solution
Methodology:Quantitative
Sample Size:750
Targeted Audience:Biopharma executives, Healthcare Policy Makers, Senior Business Decision makers
Impact
Creatively positioning the client as a thought leader in the industry
Better articulating its role in helping countries and businesses to tackle the complex dynamics in the fluctuating world of biopharma:
